360 Series Panel Collection

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

Ideal for studying solid tumors, the 360 Series Panel Collection can be used to better understand the biology behind therapeutic response, therapeutic mechanism of action, immune evasion, and the interplay between the tumor and microenvironment. These panels serve as powerful tools for developing novel signatures that correlate with response and/or survival.

  • 1,588 unique genes included across all panels
  • PAM50, Claudin-Low, & Triple Negative Breast Cancer (TNBC) gene signatures included in the Breast Cancer 360 Panel
  • Data Analysis Service for the IO 360 and Breast Cancer 360 Panels provides interactive and customizable reports with signatures scores
  • Pairs with GeoMx® Cancer Transcriptome Atlas for comparative spatial RNA profiling

How It Works

Selecting your panel
Tumor Inflammation Signature
Product Bulletins
Selecting your panel

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Tumor Inflammation Signature

The Tumor Inflammation Signature1 includes 18 functional genes often associated with the response to PD-1/PD-L1 checkpoint inhibitors. It is embedded into all of the 360 series panels: The PanCancer IO 360 Panel, the Breast Cancer 360 Panel, and the Tumor Signaling 360 Panel.

  • Includes four areas of immune biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
  • Highlights the complex biology of the host immune microenvironment.

View publication and video.

1. Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).

Related Resources

See all resources
Product Bulletin Breast Cancer 360 – Product Bulletin
Product Bulletin PanCancer IO 360 Panel- Product Bulletin
Product Bulletin Tumor Signaling 360 Panel – Product Bulletin
Product Bulletin GeoMx Cancer Transcriptome Atlas (CTA) – Product Bulletin


View all publications

The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma.

Background: Tertiary lymphoid structures (TLSs) play key roles in tumour adaptive immunity. However, the prognostic value and molecular properties of TLSs in oesophageal squamous cell carcinoma (ESCC) patients have not been studied.

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.

While great strides have been made in the treatment of advanced renal cell carcinoma (RCC) with the emergence of immune checkpoint inhibitors (ICIs) and VEGFR-targeting drugs, sizable proportions of patients still do not respond to upfront therapy and long-term responses only occur in a minority of patients. There is therefore a great need for the development of better predictors of response and an increased understanding of mechanisms of resistance to these therapies.

The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis.

Brain metastases (BrMs) are a common occurrence in lung cancer with a dismal outcome. To understand the mechanism of metastasis to inform prognosis and treatment, here we analyze primary and metastasized tumor specimens from 44 non-small cell lung cancer patients by spatial RNA sequencing, affording a whole transcriptome map of metastasis resolved with morphological markers for the tumor core, tumor immune microenvironment (TIME), and tumor brain microenvironment (TBME).


Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us